On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy pill — the first daily glucagon-like peptide-1 (GLP-1) receptor agonist tablet licensed for weight management in the United Kingdom.[1] The decision means semaglutide, the active ingredient already familiar to UK patients as a weekly injection, can now be prescribed in oral tablet form.
This page is a clinical reference for patients who want to understand what has been approved, what the evidence shows, how the tablet is taken, what the safety profile looks like, and where availability currently stands in the UK.
It is not a promotional page. Wegovy pill is a prescription-only medicine. The information below is provided for the benefit of patients already engaged in regulated clinical care, to help them have an informed conversation with their clinician about whether — and when — this option may be appropriate for their treatment.
What has been approved
The MHRA has licensed Wegovy pill (semaglutide tablets) as a once-daily oral medication for weight management.[1] It is the same active ingredient as the once-weekly Wegovy injection, formulated as a tablet using an absorption enhancer that allows a portion of the dose to cross the stomach lining intact.
Wegovy pill is licensed in the UK as an adjunct to a reduced-calorie diet and increased physical activity in:
- Adults with obesity, defined as a body mass index (BMI) of 30 kg/m² or above
- Adults living with overweight, defined as a BMI of 27 kg/m² to less than 30 kg/m², with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)
The UK is the third regulatory authority to license this formulation, following the US Food and Drug Administration in January 2026[2] and the United Arab Emirates Emirates Drug Establishment.
When Wegovy pill will be available in the UK
Wegovy pill is approved but not yet commercially available. Novo Nordisk has indicated a UK launch in the second half of 2026, with private prescription access expected first.[3] The medication is not currently available on the NHS; NICE will conduct a separate Technology Appraisal to determine NHS access criteria, which typically takes 6–12 months following MHRA approval.[4]
he Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) — the documents that set out the full prescribing schedule, contraindications, and safety profile — are expected to be published by the MHRA within seven days of the 11 June approval.[1]
The clinical evidence — OASIS 4
The MHRA's approval is based primarily on data from the OASIS 4 phase 3 clinical trial.[5]
OASIS 4 was a 64-week randomised controlled trial assessing once-daily oral semaglutide against placebo, in adults with obesity, alongside lifestyle modifications. The trial reported two pre-specified analyses: an on-treatment analysis assessing outcomes in those who remained on treatment, and a treatment policy analysis reflecting outcomes regardless of treatment discontinuation.
Under the treatment policy analysis — the conservative measure that reflects real-world adherence variability — adults receiving semaglutide tablets at the 25mg target dose achieved an average weight reduction of approximately 13.6 percent of initial body weight at 64 weeks, compared with approximately 2.4 percent in the placebo group.[5]
This is broadly comparable to the weight reduction observed with the weekly Wegovy injection at its 2.4mg target dose in the STEP 1 trial.[6] It is lower than the weight reduction observed in trials of tirzepatide (a different medication with a different mechanism), which has typically reported approximately 20 percent at higher doses in the SURMOUNT-1 trial.[7]
Trial data is not a personal outcome prediction. Individual results vary considerably with adherence, dose escalation tolerance, lifestyle change, and other clinical factors.
Wegovy pill vs Wegovy injection — side by side
Both formulations contain the same active ingredient, semaglutide, and work through the same mechanism. The differences are practical rather than pharmacological.
The choice between routes is a clinical conversation. There is no single "better" option — there is the option that best fits the individual's clinical picture, lifestyle, and routine.
Dosing and administration
Wegovy pill is taken once daily, first thing in the morning, on an empty stomach, with a small sip of plain water only.
Strict administration requirements apply:
- Overnight fast of at least 8 hours before the dose
- Plain water only when swallowing the tablet — not coffee, tea, juice, or any other liquid
- Wait at least 30 minutes after the dose before consuming any food, drink, or other oral medications
These conditions are not optional. They are a function of how the oral formulation is absorbed: food, other liquids, and other medications substantially reduce the amount of semaglutide that reaches the bloodstream, which materially reduces effectiveness.
Treatment begins at a low starter dose and is escalated stepwise over a period of several months to the maintenance dose.[5] The full prescribing schedule, including dose increments and timing, is set out in the SmPC.
Patients should not adjust their dose without clinical guidance. Skipping doses, doubling doses to compensate, or self-escalating the dose carries real safety and tolerability consequences.
Side effects
The side-effect profile of oral semaglutide is broadly similar to that of injectable semaglutide.[5][6]
Common side effects (affecting more than 1 in 10 people in clinical trials):
- Nausea, particularly during dose escalation
- Vomiting
- Diarrhoea or constipation
- Reduced appetite
- Abdominal discomfort or pain
- Fatigue
These are generally most pronounced during the first weeks of treatment and during dose escalation, and tend to settle for most patients as the body adjusts.
Less common but more serious effects can include pancreatitis (inflammation of the pancreas), gallbladder disease (including gallstones), changes in vision in people with diabetic retinopathy, and rare hypersensitivity reactions.[1][5] The full safety profile is set out in the SmPC and Patient Information Leaflet.
Any patient experiencing severe or persistent abdominal pain, persistent vomiting, signs of pancreatitis, or signs of an allergic reaction should seek urgent medical advice. Suspected side effects should be reported through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.[8]
Who Wegovy pill is not appropriate for
Wegovy pill is not licensed or appropriate for:
- Pregnancy or breastfeeding
- People with a personal or family history of medullary thyroid carcinoma
- People with multiple endocrine neoplasia type 2
- People with type 1 diabetes (it is not a substitute for insulin)
- Children and adolescents under 18 (no licence in this group)
- People with severe gastrointestinal disease or a history of pancreatitis (relative contraindication — clinician judgement)
Other contraindications and precautions exist; the complete list is in the SmPC. Patients with comorbidities — particularly cardiovascular, renal, hepatic, or thyroid conditions — should have a thorough clinical review before any treatment change.
Cost and access in the UK
Wegovy pill is not yet on the NHS. At UK launch, access will be through private prescription only. Pricing for the UK market has not yet been published by Novo Nordisk and will be confirmed at commercial launch.[3]
Indicative context: the US list price of Wegovy pill is broadly comparable to the US list price of Wegovy injection at the equivalent treatment level. Whether UK pricing follows the same pattern depends on the commercial decisions Novo Nordisk takes at launch and the pricing decisions individual UK providers make thereafter.
NHS access via NICE Technology Appraisal will be a separate process, typically taking 6–12 months from regulatory approval.[4] Patients in NHS weight management services should not expect Wegovy pill availability through the NHS in 2026.
Patients should not source Wegovy pill from sources outside regulated UK clinical practice. Counterfeit and unregulated semaglutide products are an active safety concern and are not subject to MHRA oversight.
Availability at VSC
When Wegovy pill becomes commercially available in the UK, VSC will offer it as part of our weight management programme. Access will follow our standard clinical pathway:
- Clinical assessment considering your full medical history, current treatment, lifestyle, and goals
- Clinical recommendation from our team on whether a treatment change is appropriate
- Dispensing through our GPhC-registered pharmacy partner
- Ongoing monitoring and support as standard
Patients currently in active treatment with VSC do not need to take any action at this point. When Wegovy pill is available and if a treatment review is clinically appropriate for you, your clinician will discuss it with you directly through the portal.
If you have specific questions about whether Wegovy pill might be appropriate for your situation in due course, please message your clinician through the portal. We will respond as part of standard clinical care.
Frequently asked questions
Is Wegovy pill the same medication as the Wegovy injection?
The active ingredient is the same — semaglutide. The formulation, dose, and administration differ. Wegovy pill is a 25mg tablet taken once daily; Wegovy injection is a 2.4mg dose given subcutaneously once weekly. Average weight reduction in trials is broadly comparable.
Can I switch from Wegovy injection to Wegovy pill?
Possibly, when Wegovy pill becomes commercially available. Any switch between formulations requires a clinical assessment — it is not a like-for-like swap, and the dose escalation schedule restarts on transition. For VSC patients currently in active treatment, your clinician will discuss this with you when the medication is available and if it is clinically appropriate.
What happens if I miss a dose?
The recommended approach is to take the missed dose as soon as you remember on the same day, provided the conditions for administration (fasted, plain water only, 30-minute wait before food) can still be met. Do not double up. Doubling doses to "make up" carries side-effect risk and is not effective.
Does Wegovy pill need to be refrigerated?
No. Unlike Wegovy injection, the tablet formulation does not require refrigeration. This makes travel and storage simpler.
Why does Wegovy pill require fasting before and after the dose?
The oral formulation uses an absorption enhancer to allow a portion of the semaglutide dose to cross the stomach lining. Food, other liquids, and other medications interfere with this absorption and substantially reduce how much medication reaches the bloodstream. The fasting window is what makes the formulation effective.
Will Wegovy pill be available on the NHS?
Not initially. NICE will conduct a Technology Appraisal to determine NHS access criteria, which typically takes 6–12 months following MHRA approval. NHS access in 2026 is unlikely.
When will Wegovy pill be available in the UK?
Novo Nordisk has indicated a UK launch in the second half of 2026, through private prescription initially. An exact launch date has not been published.
Is Wegovy pill safer than Wegovy injection?
No. The safety profile, contraindications, and monitoring requirements are broadly similar. The route of administration changes the practical experience but does not substantially change the safety considerations.
Important safety information
Wegovy pill (semaglutide tablets) is a prescription-only medicine. It should not be obtained from sources outside regulated clinical practice. Counterfeit and unregulated semaglutide products carry serious safety risks and are not subject to MHRA oversight.
Suspected side effects should be reported through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.[8]
Weight management medications are most effective when paired with sustained lifestyle change. The OASIS 4 trial showed weight reduction of approximately 13.6 percent under conditions of medication plus reduced-calorie diet plus increased physical activity.[5] Medication alone is not the intervention.
References
[1] Medicines and Healthcare products Regulatory Agency. MHRA approves new oral weight-loss medication Wegovy tablets for use in Great Britain. 11 June 2026. Available at: https://www.gov.uk/government/news (MHRA news archive).
[2] US Food and Drug Administration. FDA approves oral semaglutide for chronic weight management. January 2026.
[3] Novo Nordisk. Wegovy oral semaglutide regulatory milestones — investor communications. June 2026.
[4] National Institute for Health and Care Excellence. NG246: Obesity — identification, assessment and management. 2025. Available at: https://www.nice.org.uk/guidance/ng246
[5] OASIS 4 trial — Phase 3 randomised controlled trial of oral semaglutide 25mg for weight management. Novo Nordisk clinical trial data submitted to MHRA, 2025–2026.
[6] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
[7] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
[8] MHRA Yellow Card Scheme — suspected adverse drug reaction reporting. Available at: https://yellowcard.mhra.gov.uk
[9] Committee of Advertising Practice / Advertising Standards Authority / Medicines and Healthcare products Regulatory Agency / General Pharmaceutical Council. Joint Enforcement Notice: Prescription-only medicines used for weight management. April 2025, updated September 2025.
[10] CAP. AdviceOnline: Weight control — Prescription-only medicines. Updated 20 March 2026. Available at: https://www.asa.org.uk/advice-online
.avif)